[Featured Stock] Vibozone Pharmaceutical Surges Intraday on 'Unqualified' Audit Report
Bioson Pharmaceutical is showing strong intraday gains following news that it received an 'unqualified' opinion from an external auditor on last year's financial statements.
As of 10:26 AM on the 29th, Bioson Pharmaceutical's stock price is at 1,137 KRW, up 13.13% compared to the previous trading day. The stock surged to as high as 1,267 KRW during the session.
The day before, Bioson Pharmaceutical announced that it received an unqualified audit opinion from Hyundai Accounting Corporation. Bioson Pharmaceutical completed the domestic Phase 3 clinical trial of the non-narcotic analgesic injection 'Opirangerin (VVZ-149)' and announced results statistically proving its efficacy in postoperative pain relief. Based on the clinical results, Bioson Pharmaceutical plans to apply for product approval from the Ministry of Food and Drug Safety.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Jeong Yu-kyung Is a Neighbor"...Itaewon Standalone House with Record 23.2 Billion Won Appraisal Up for Auction [Real Estate AtoZ]
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
A company representative stated, "Although we disclosed a delay in submitting the audit report on the 22nd and there were some concerns regarding the audit opinion, these were resolved with the unqualified opinion. We will further supplement and improve our internal accounting management system to manage it more transparently in the future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
